ATE202383T1 - Zusammensetzungen und verfahren für die behandlung von mit hepatitis c viren assoziierten krankheiten - Google Patents

Zusammensetzungen und verfahren für die behandlung von mit hepatitis c viren assoziierten krankheiten

Info

Publication number: ATE202383T1
Authority: AT; Austria
Prior art keywords: hepatitis; virus; methods; compositions; treatment
Prior art date: 1992-09-10

Application number

AT93919644T

Other languages

English (en)

Inventor

Kevin P Anderson

Ronnie C Hanecak

Kazuya Hoshiko

Chikateru Nozaki

Tsukasa Nishihara

Hiroshi Nakatake

Fukusaburo Hamada

Tatsuo Eto

Shinichi Furukawa

Original Assignee

Isis Pharmaceuticals Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1992-09-10

Filing date

1993-09-10

Publication date

2001-07-15

1993-04-14 Priority claimed from JP5087195A external-priority patent/JPH06296492A/ja

1993-09-10 Application filed by Isis Pharmaceuticals Inc filed Critical Isis Pharmaceuticals Inc

2001-07-15 Application granted granted Critical

2001-07-15 Publication of ATE202383T1 publication Critical patent/ATE202383T1/de

Links

201000010099 disease Diseases 0.000 title abstract 3
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title abstract 3
238000000034 method Methods 0.000 title abstract 2
208000006454 hepatitis Diseases 0.000 title 1
231100000283 hepatitis Toxicity 0.000 title 1
239000000203 mixture Substances 0.000 title 1
241000711549 Hepacivirus C Species 0.000 abstract 2
150000001875 compounds Chemical class 0.000 abstract 2
108020000948 Antisense Oligonucleotides Proteins 0.000 abstract 1
108091034117 Oligonucleotide Proteins 0.000 abstract 1
JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 abstract 1
239000000074 antisense oligonucleotide Substances 0.000 abstract 1
238000012230 antisense oligonucleotides Methods 0.000 abstract 1
230000000295 complement effect Effects 0.000 abstract 1
238000001514 detection method Methods 0.000 abstract 1
238000003745 diagnosis Methods 0.000 abstract 1
230000000694 effects Effects 0.000 abstract 1
238000000338 in vitro Methods 0.000 abstract 1
238000001727 in vivo Methods 0.000 abstract 1
230000002401 inhibitory effect Effects 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1131—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
- C12Q1/701—Specific hybridization probes
- C12Q1/706—Specific hybridization probes for hepatitis
- C12Q1/707—Specific hybridization probes for hepatitis non-A, non-B Hepatitis, excluding hepatitis D
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/33—Chemical structure of the base
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/352—Nature of the modification linked to the nucleic acid via a carbon atom
- C12N2310/3521—Methyl
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/352—Nature of the modification linked to the nucleic acid via a carbon atom
- C12N2310/3527—Other alkyl chain
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
- C12N2770/24222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
Genetics & Genomics (AREA)
Molecular Biology (AREA)
Biochemistry (AREA)
General Health & Medical Sciences (AREA)
Wood Science & Technology (AREA)
Biotechnology (AREA)
Zoology (AREA)
Virology (AREA)
Bioinformatics & Cheminformatics (AREA)
Biophysics (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Biomedical Technology (AREA)
General Engineering & Computer Science (AREA)
Communicable Diseases (AREA)
Immunology (AREA)
Physics & Mathematics (AREA)
Microbiology (AREA)
Medicinal Chemistry (AREA)
Analytical Chemistry (AREA)
Gastroenterology & Hepatology (AREA)
Plant Pathology (AREA)
Oncology (AREA)
Chemical Kinetics & Catalysis (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Saccharide Compounds (AREA)

AT93919644T 1992-09-10 1993-09-10 Zusammensetzungen und verfahren für die behandlung von mit hepatitis c viren assoziierten krankheiten ATE202383T1 (de)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US94528992A	1992-09-10	1992-09-10
JP5087195A JPH06296492A (ja)	1993-04-14	1993-04-14	抗ｃ型肝炎ウイルスオリゴヌクレオチド
PCT/JP1993/001293 WO1994005813A1 (en)	1992-09-10	1993-09-10	Compositions and methods for treatment of hepatitis c virus-associated diseases

Publications (1)

Publication Number	Publication Date
ATE202383T1 true ATE202383T1 (de)	2001-07-15

Family

ID=26428490

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT93919644T ATE202383T1 (de)	1992-09-10	1993-09-10	Zusammensetzungen und verfahren für die behandlung von mit hepatitis c viren assoziierten krankheiten

Country Status (10)

Country	Link
US (2)	US6284458B1 (de)
EP (1)	EP0662157B1 (de)
JP (1)	JPH08506479A (de)
AT (1)	ATE202383T1 (de)
AU (1)	AU680435B2 (de)
CA (1)	CA2143678A1 (de)
DE (1)	DE69330372T2 (de)
DK (1)	DK0662157T3 (de)
NZ (2)	NZ255578A (de)
WO (1)	WO1994005813A1 (de)

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6174868B1 (en) *	1992-09-10	2001-01-16	Isis Pharmaceuticals, Inc.	Compositions and methods for treatment of hepatitis C virus-associated diseases
DE69333914T2 (de) *	1992-09-28	2006-08-10	Chiron Corp., Emeryville	Verfahren und zusammensetzungen zur kontrolle der übersetzung der hcv-proteine
US6824976B1 (en)	1993-04-02	2004-11-30	Rigel Pharmaceuticals, Inc.	Method for selective inactivation of viral replication
JPH10503364A (ja) *	1994-05-10	1998-03-31	ザジェネラルホスピタルコーポレーション	Ｃ型肝炎ウイルスのアンチセンス阻害
ZA964446B (en) *	1995-06-06	1996-12-06	Hoffmann La Roche	Oligonucleotides specific for hepatitis c virus
CA2223103A1 (en) *	1995-06-06	1996-12-12	Isis Pharmaceuticals Inc.	Oligonucleotides having phosphorothioate linkages of high chiral purity
US6090557A (en) *	1997-04-18	2000-07-18	Roche Molecular Systems, Inc.	Neisseria gonorrhoeae-specific oligonucleotides
EP1002878A3 (de) *	1998-11-19	2003-11-12	Tosoh Corporation	Hepatitis C Viren RNS-bindendes oligo DNS und Verfahren für dessen Herstellung
PY0111577A (es)	2000-05-23	2017-01-02	Idenix Cayman Ltd	Métodos y composiciones para el tratamiento del virus de la hepatitis c
BR0111196A (pt)	2000-05-26	2004-04-06	Idenix Cayman Ltd	Composições e uso das mesmas para tratamento de flavivìrus e pestivìrus
US20030059443A1 (en) *	2001-08-22	2003-03-27	Ecker David J.	Molecular interaction sites of hepatitis C virus RNA and methods of modulating the same
WO2003025173A1 (en) *	2001-09-17	2003-03-27	Takeshi Imanishi	Novel antisense oligonucleotide derivatives to hepatitis c virus
RU2005118421A (ru)	2002-11-15	2006-01-20	Айденикс (Кайман) Лимитед (Ky)	2'-разветвленные нуклеозиды и мутация flaviviridae
FR2848572B1 (fr) *	2002-12-12	2005-12-09	Univ Joseph Fourier	Molecules inhibitrices de la synthese proteique du virus de l'hepatite c et procede de criblage desdites molecules inhibitrices
US7833987B2 (en) *	2004-03-12	2010-11-16	Indian Institute Of Science	Small synthetic RNA, a method of preparing the same and uses thereof
ES2362670T3 (es) *	2004-09-24	2011-07-11	Alnylam Pharmaceuticals, Inc	Orientación a intermedios de replicación de hebra no codificante de virus monocatenarios por arni.
FR2884522A1 (fr) *	2005-04-19	2006-10-20	Larissa Balakireva	Methode d'inhibition de la traduction et/ou la replication d'une sequence d'arn par multimerisation d'une de ses regions d'arn non codant replie
EP2007889A2 (de)	2006-04-03	2008-12-31	Santaris Pharma A/S	Pharmazeutische zusammensetzungen mit anti-mirna-antisense-oligonukleotiden
EA201100813A1 (ru)	2006-04-03	2012-06-29	Сантарис Фарма А/С	Фармацевтическая композиция
ES2603379T3 (es) *	2006-10-09	2017-02-27	Roche Innovation Center Copenhagen A/S	Compuestos antagonistas de ARN para la modulación de PCSK9
US8481506B2 (en) *	2006-12-05	2013-07-09	Rosetta Genomics, Ltd.	Nucleic acids involved in viral infection
US20080261913A1 (en)	2006-12-28	2008-10-23	Idenix Pharmaceuticals, Inc.	Compounds and pharmaceutical compositions for the treatment of liver disorders
US8580756B2 (en) *	2007-03-22	2013-11-12	Santaris Pharma A/S	Short oligomer antagonist compounds for the modulation of target mRNA
US8470791B2 (en)	2007-03-22	2013-06-25	Santaris Pharma A/S	RNA antagonist compounds for the inhibition of Apo-B100 expression
JP2010529847A (ja)	2007-06-14	2010-09-02	ミルクスセラピューティクスアンパーツゼルスカブ	標的ｒｎａ活性の調節のためのオリゴヌクレオチド
US20110054011A1 (en) *	2007-08-30	2011-03-03	Mccullagh Keith	RNA Antagonist Compounds for the Modulation of FABP4/AP2
CN101821391B (zh)	2007-10-04	2016-04-27	桑塔里斯制药公司	微小聚体
CA2717792A1 (en) *	2008-03-07	2009-09-11	Santaris Pharma A/S	Pharmaceutical compositions for treatment of microrna related diseases
US8492357B2 (en)	2008-08-01	2013-07-23	Santaris Pharma A/S	Micro-RNA mediated modulation of colony stimulating factors
ES2599979T3 (es) *	2009-04-24	2017-02-06	Roche Innovation Center Copenhagen A/S	Composiciones farmacéuticas para el tratamiento de pacientes de VHC que no responden al interferón
EP2456870A1 (de)	2009-07-21	2012-05-30	Santaris Pharma A/S	Auf pcsk9 gerichtete antisense-oligomere
WO2012007477A1 (en) *	2010-07-12	2012-01-19	Santaris Pharma A/S	Anti hcv oligomers
US9328346B2 (en)	2010-11-12	2016-05-03	The General Hospital Corporation	Polycomb-associated non-coding RNAs
CA2843324A1 (en)	2011-03-31	2012-11-15	Idenix Pharmaceuticals, Inc.	Compounds and pharmaceutical compositions for the treatment of viral infections
TW201329096A (zh)	2011-09-12	2013-07-16	Idenix Pharmaceuticals Inc	經取代羰氧基甲基磷酸醯胺化合物及用於治療病毒感染之藥學組成物
WO2013056046A1 (en)	2011-10-14	2013-04-18	Idenix Pharmaceuticals, Inc.	Substituted 3',5'-cyclic phosphates of purine nucleotide compounds and pharmaceutical compositions for the treatment of viral infections
US10837014B2 (en)	2012-05-16	2020-11-17	Translate Bio Ma, Inc.	Compositions and methods for modulating SMN gene family expression
EA201492116A1 (ru)	2012-05-16	2015-05-29	Рана Терапьютикс, Инк.	Композиции и способы для модулирования экспрессии mecp2
US9109001B2 (en)	2012-05-22	2015-08-18	Idenix Pharmaceuticals, Inc.	3′,5′-cyclic phosphoramidate prodrugs for HCV infection
EP2852605B1 (de)	2012-05-22	2018-01-31	Idenix Pharmaceuticals LLC	3',5'-cyclische phosphat-prodrugs für hcv-infektion
EP2852603B1 (de)	2012-05-22	2021-05-12	Idenix Pharmaceuticals LLC	D-aminosäure-verbindungen gegen lebererkrankungen
TW201408688A (zh)	2012-05-25	2014-03-01	Janssen R & D Ireland	尿嘧啶基螺氧環丁烷（ｓｐｉｒｏｏｘｅｔａｎｅ）核苷類
WO2014052638A1 (en)	2012-09-27	2014-04-03	Idenix Pharmaceuticals, Inc.	Esters and malonates of sate prodrugs
SG11201502750UA (en)	2012-10-08	2015-06-29	Idenix Pharmaceuticals Inc	2'-chloro nucleoside analogs for hcv infection
EP2722397B1 (de) *	2012-10-18	2017-12-13	F. Hoffmann-La Roche AG	Test mit zwei Sonden zur Erkennung von heterogenen Amplikonpopulationen
EP2909222B1 (de)	2012-10-22	2021-05-26	Idenix Pharmaceuticals LLC	2',4'-verbrückten nukleoside für hcv-infektion
US10260089B2 (en)	2012-10-29	2019-04-16	The Research Foundation Of The State University Of New York	Compositions and methods for recognition of RNA using triple helical peptide nucleic acids
WO2014099941A1 (en)	2012-12-19	2014-06-26	Idenix Pharmaceuticals, Inc.	4'-fluoro nucleosides for the treatment of hcv
US11274998B2 (en)	2012-12-26	2022-03-15	Ventana Medical Systems, Inc.	Specimen processing systems and methods for holding slides
WO2014137930A1 (en)	2013-03-04	2014-09-12	Idenix Pharmaceuticals, Inc.	Thiophosphate nucleosides for the treatment of hcv
EP2970358B1 (de)	2013-03-04	2021-06-30	Idenix Pharmaceuticals LLC	3'-deoxy-nukleoside zur behandlung von hcv
EP2970357B1 (de)	2013-03-13	2025-01-01	Idenix Pharmaceuticals LLC	Aminosäure-phosphoramidat-pronukleotide von 2'-cyano-, azido- und aminonukleosiden zur behandlung von hcv
WO2014165542A1 (en)	2013-04-01	2014-10-09	Idenix Pharmaceuticals, Inc.	2',4'-fluoro nucleosides for the treatment of hcv
KR20160003700A (ko)	2013-04-12	2016-01-11	아칠리온 파르마세우티칼스 인코포레이티드	C형간염 바이러스의 치료를 위한 고활성 뉴클레오시드 유도체
EP3004130B1 (de)	2013-06-05	2019-08-07	Idenix Pharmaceuticals LLC.	1',4'-thionukleoside zur behandlung von hcv
MX391977B (es)	2013-06-27	2025-03-21	Roche Innovation Ct Copenhagen As	Oligómeros antisentido y conjugados con diana en la proteína-convertasa subtilisina/kexina tipo 9(pcsk9).
EP3027636B1 (de)	2013-08-01	2022-01-05	Idenix Pharmaceuticals LLC	D-amino acid phosphoramidate pronucleotide of halogenierte pyrimidine verbindungen für leber krankheiten
EP3131914B1 (de)	2014-04-16	2023-05-10	Idenix Pharmaceuticals LLC	3'-substituierte methyl- oder alkynylnukleoside zur behandlung von hcv
CA2966044A1 (en)	2014-10-30	2016-05-06	The General Hospital Corporation	Methods for modulating atrx-dependent gene repression
US10758558B2 (en)	2015-02-13	2020-09-01	Translate Bio Ma, Inc.	Hybrid oligonucleotides and uses thereof
WO2016149455A2 (en)	2015-03-17	2016-09-22	The General Hospital Corporation	The rna interactome of polycomb repressive complex 1 (prc1)

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5034506A (en) *	1985-03-15	1991-07-23	Anti-Gene Development Group	Uncharged morpholino-based polymers having achiral intersubunit linkages
US4806463A (en) *	1986-05-23	1989-02-21	Worcester Foundation For Experimental Biology	Inhibition of HTLV-III by exogenous oligonucleotides
US5194428A (en) *	1986-05-23	1993-03-16	Worcester Foundation For Experimental Biology	Inhibition of influenza virus replication by oligonucleotide phosphorothioates
US5264423A (en) *	1987-03-25	1993-11-23	The United States Of America As Represented By The Department Of Health And Human Services	Inhibitors for replication of retroviruses and for the expression of oncogene products
US5276019A (en) *	1987-03-25	1994-01-04	The United States Of America As Represented By The Department Of Health And Human Services	Inhibitors for replication of retroviruses and for the expression of oncogene products
US5714596A (en)	1987-11-18	1998-02-03	Chiron Corporation	NANBV diagnostics: polynucleotides useful for screening for hepatitis C virus
CN1074422C (zh)	1987-11-18	2001-11-07	希龙股份有限公司	制备含有hcv表位的分离多肽的方法
US5004810A (en) *	1988-09-30	1991-04-02	Schering Corporation	Antiviral oligomers
JP2656995B2 (ja) *	1989-03-17	1997-09-24	カイロンコーポレイション	Ｎａｎｂｖの診断用薬
US5166195A (en) *	1990-05-11	1992-11-24	Isis Pharmaceuticals, Inc.	Antisense inhibitors of the human immunodeficiency virus phosphorothioate oligonucleotides
WO1992002642A1 (en) *	1990-08-10	1992-02-20	Chiron Corporation	Nanbv diagnostics: polynucleotides useful for screening for hepatitis c virus
AU1459792A (en) *	1991-01-14	1992-08-27	James N. Gamble Institute Of Medical Research	Basic structural immunogenic polypeptides having epitopes for hcv, antibodies, polynucleotide sequences, vaccines and methods
DK0585398T3 (da) *	1991-05-08	2004-02-02	Chiron Corp	HCV genomiske sekvenser til diagnostiske og terapeutiske midler
CA2070952A1 (en) *	1991-06-11	1992-12-12	Makoto Seki	Gene of hepatitis c virus or fragment thereof, polypeptide encoded by the same
US5610054A (en) *	1992-05-14	1997-03-11	Ribozyme Pharmaceuticals, Inc.	Enzymatic RNA molecule targeted against Hepatitis C virus
US5922857A (en)	1992-09-28	1999-07-13	Chiron Corporation	Methods and compositions for controlling translation of HCV proteins
JP3028171B2 (ja) *	1993-08-31	2000-04-04	日本ピラー工業株式会社	複合ガスケット

1993
- 1993-09-10 US US08/397,220 patent/US6284458B1/en not_active Expired - Fee Related
- 1993-09-10 EP EP93919644A patent/EP0662157B1/de not_active Expired - Lifetime
- 1993-09-10 DK DK93919644T patent/DK0662157T3/da active
- 1993-09-10 DE DE69330372T patent/DE69330372T2/de not_active Expired - Lifetime
- 1993-09-10 CA CA002143678A patent/CA2143678A1/en not_active Abandoned
- 1993-09-10 NZ NZ255578A patent/NZ255578A/en unknown
- 1993-09-10 JP JP6507055A patent/JPH08506479A/ja active Pending
- 1993-09-10 AT AT93919644T patent/ATE202383T1/de not_active IP Right Cessation
- 1993-09-10 NZ NZ286209A patent/NZ286209A/xx unknown
- 1993-09-10 AU AU49837/93A patent/AU680435B2/en not_active Expired
- 1993-09-10 WO PCT/JP1993/001293 patent/WO1994005813A1/en not_active Ceased
2003
- 2003-06-09 US US10/457,304 patent/US20040033978A1/en not_active Abandoned

Also Published As

Publication number	Publication date
US6284458B1 (en)	2001-09-04
DK0662157T3 (da)	2001-08-27
DE69330372D1 (de)	2001-07-26
AU4983793A (en)	1994-03-29
EP0662157B1 (de)	2001-06-20
WO1994005813A1 (en)	1994-03-17
JPH08506479A (ja)	1996-07-16
AU680435B2 (en)	1997-07-31
NZ286209A (en)	2000-09-29
CA2143678A1 (en)	1994-03-17
DE69330372T2 (de)	2002-03-14
US20040033978A1 (en)	2004-02-19
NZ255578A (en)	1996-11-26
EP0662157A1 (de)	1995-07-12

Legal Events

Date	Code	Title	Description
2006-06-15	REN	Ceased due to non-payment of the annual fee

Publication	Publication Date	Title
ATE202383T1 (de)	2001-07-15	Zusammensetzungen und verfahren für die behandlung von mit hepatitis c viren assoziierten krankheiten
ATE289519T1 (de)	2005-03-15	Zusammensetzungen und verfahren zur behandlung von hepatitis c virus-bedingten erkrankungen
UA41879C2 (uk)	2001-10-15	Засіб для лікування мотонейронових захворювань
DE3876125D1 (de)	1993-01-07	Behandlung der menschlichen viralinfektion durch doppelstrang-rna, kombiniert mit viralen inhibitoren.
ATE179330T1 (de)	1999-05-15	Verbesserte alpha-interferon-zusammensetzung und verfahren zu ihrer herstellung aus leukocyten des menschlichen peripheren blute
WO1992019743A3 (en)	1993-11-25	Hcv genomic sequences for diagnostics and therapeutics
NO930514L (no)	1993-04-02	Hemming av influensavirus type a, ann arbor-stamme h2n2 med antisenseoligonukleotider
MY128441A (en)	2007-02-28	Bipiperidine derivatives as modulators of ccr3 activity and as h1 antogonists
DE69833971D1 (de)	2006-05-11	Verfahren zur behandlung von alzheimerschen krankheit
NO954217L (no)	1995-12-18	Guanosinrike antivirus-oligonukleotider
ATE465168T1 (de)	2010-05-15	Xylo-lna analoge
ATE211393T1 (de)	2002-01-15	Zusammensetzung die mindestens ein doppel strangiges rna und mindestens ein interferon enthält, zur behandlung von virale hepatitis
ATE202140T1 (de)	2001-06-15	Hemmung der neovaskulasierung durch vegf- spezifische oligonukleotide
HRP20030139B1 (hr)	2015-08-28	Peptidomimetiäśki inhibitori proteaza
PL316197A1 (en)	1996-12-23	Benzothiophene, benzofuran and indole thiazepinones, oxazepinones and diazepinones as agents preventing adhesion of cells and inhibiting activity of hiv virus
DE69626393D1 (de)	2003-04-03	Spezifische oligonukleotide für hepatitis b virus
EP0745090A1 (de)	1996-12-04	Oligonukleotide mit antirespiratorischer synzytialvirus-wirkung
DE60002126D1 (de)	2003-05-22	Substituierte dimere Carboxamid-Derivate, Verfahren zu ihrer Herstellung und sie enthaltende pharmazeutische Zubereitungen
FR2678284B1 (fr)	1993-10-08	Sequences d'adn derivees du genome du papillomavirus hpv42, application de ces sequences au diagnostic in vitro d'infection par ce papillomavirus et a la production de compositions immunogenes.
MXPA02011969A (es)	2004-09-06	Metodos para el tratamiento de padecimientos virales con il-18 y combinaciones de il-18.
TNSN00034A1 (fr)	2005-11-10	Derives de 2-aminopyridine nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant
DE3583400D1 (de)	1991-08-08	Zubereitungen und verfahren zum schutz von t-lymphozyten gegen das krankheitsagens von lymphadenopathie und vom erworbenen immundepressionsyndrom.
MD940152A (ro)	1995-12-31	Compoziţie farmaceutică pentru tratarea infecţiilor şi bolilor, provocate de virusul hepatitei V (HBV)
ATE79034T1 (de)	1992-08-15	Behandlung von viruskrankheiten.
ES2093554A1 (es)	1996-12-16	Procedimientos de amplificacion de genoma y mezclas de oligonucleotidos iniciadores para la deteccion y la identificacion de agentes infecciosos relacionados.